Phase 3 Trial for Agitation in Alzheimer’s, Dementia Patients Initiated by Intra-Cellular Therapies

Phase 3 Trial for Agitation in Alzheimer’s, Dementia Patients Initiated by Intra-Cellular Therapies
New York City-based Intra-Cellular Therapies has started its ITI-007-201 Phase 3 clinical trial for the treatment of agitation in patients with dementia, including Alzheimer’s disease, following the company’s communication with the U.S. FDA. Intra-Cellular Therapies Chairman and CEO Dr. Sharon Mates said in a press release she is pleased that ITI-007 is advancing into Phase 3 development to treat

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *